Clinical Practice Consensus Statement 2025: Management of Hyperuricemia and Gout in Adolescents. [PDF]
Li C +23 more
europepmc +1 more source
Treatment-emergent major adverse cardiovascular and thromboembolic events were infrequent during clinical trials of pegloticase. [PDF]
Troum OM +4 more
europepmc +1 more source
2024 Update of Chinese Guidelines for Management of Hyperuricemia and Gout Part II: Recommendations for Patients With Common Comorbidities. [PDF]
Li C +30 more
europepmc +1 more source
Colchicine and the risk of major adverse cardiovascular events in patients with gout and Type 2 diabetes: A nationwide cohort study. [PDF]
Jeon M +7 more
europepmc +1 more source
Group-based trajectory modeling to assess adherence to chronic urate-lowering therapies among commercially insured US adults with gout. [PDF]
Rizk JG, Qato DM, Bingham CO, dosReis S.
europepmc +1 more source
Association Between HLA-B5801 Positivity and Patient Characteristics and Clinical Outcomes in Gout. [PDF]
Ahn SS, Kim JA, Bae K.
europepmc +1 more source
Research progress on multidimensional intervention strategies for hyperuricemia: Western medicine, Traditional Chinese Medicine, and emerging therapies. [PDF]
Li X +9 more
europepmc +1 more source
The Influence of Patient Factors on the Population Pharmacokinetics of Colchicine: Implications for Safe and Effective Dosing. [PDF]
Wright DFB +6 more
europepmc +1 more source
Roles of traditional Chinese medicine extracts in hyperuricemia and gout treatment: Mechanisms and clinical applications. [PDF]
Wang YB, Jin CZ.
europepmc +1 more source

